Acute lymphoblastic leukemia (ALL) is the most common cancer in children, comprising approximately 25% of all childhood malignancies. ALL is characterized by the overproduction and accumulation of immature, abnormal white blood cells (lymphoblasts) and consecutive displacement of normal hematopoiesis. The backbone of maintenance therapy includes daily oral 6-Mercaptopurine and weekly oral Methotrexate.
This talk introduces a complete model of chemotherapy-induced leukopenia during maintenance therapy of ALL, taking the effects of two drugs in combination into consideration. Patient-specific parameters of the model are estimated. Furthermore, the ability of the proposed model to predict leukocytes over a given duration is justified by appropriate methods. All of the results here are conducted based on a real dataset collected from a local hospital.